ClinicalTrials.gg
CompletedNCT01624233UNCOVER-JUpdated Sep 10, 2019Results posted

A Study in Japanese Participants With Moderate-to-Severe Psoriasis

A Phase 3 interventional study of 80 mg ixekizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
16th of 22
91 · median 156
Started
2012
with 2 others
Phase 3
11 of 22
none open now
Registered
4th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 16th largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men must agree to use a reliable method of during the study
  • Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
  • Candidates for phototherapy and/or systemic therapy
  • Present with chronic psoriasis based on a confirmed psoriasis diagnosis for at least 6 months prior to enrollment
  • At least 10% Body Surface Area (BSA) of Psoriasis at screening and at enrollment for participants with plaque psoriasis
  • Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at enrollment for participants with plaque psoriasis

Exclusion criteria

Exclusion Criteria:

  • History of drug-induced psoriasis
  • Concurrent or recent use of any biologic agent
  • Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment for participants with plaque psoriasis
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
  • Have participated in any study with interleukin-17(IL-17) antagonists, including ixekizumab
  • Serious disorder or illness other than psoriasis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women
  • flare of psoriasis during the 12 weeks prior to enrollment for participants with plaque psoriasis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    80 mg ixekizumab

    Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.

    Drug: 80 mg ixekizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week (Wk) 12

Secondary outcomes

  1. Percentage of Participants Achieving ≥75% Improvement in PASI

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region, the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Wks 24 and 52

  2. Pharmacokinetics (PK): Ctrough at Steady State (Ctrough ss) of Ixekizumab

    PK samples were from 1 or 2 sampling cohorts. Ctrough is the minimum observed concentration of ixekizumab at steady state. Steady-state ixekizumab trough concentrations were summarized for the induction dosing period at week 12, the time of the primary efficacy assessment. Steady-state ixekizumab trough concentrations were summarized for the maintenance dosing period at week 24.

    Time frame: Pre-dose at Wks 12 (Day 84) and Wks24 (Day 168)

  3. Number of Participants With Anti-Ixekizumab Antibodies

    Treatment-emergent immunogenicity is defined as any occurrence of a 4-fold or 2-dilution increase in titer over the pretreatment baseline titer. In the case of a negative result at baseline, treatment-emergent immunogenicity is defined as an increase in titer to ≥1:10.

    Time frame: Baseline through Wk 52

  4. Percent of Participants Achieving PASI 90% and 100% Improvement

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Wks 12, 24 and 52

  5. Percentage of Participants With Static Physician Global Assessment (sPGA) (0 or 1) or sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: sPGA)

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).

    Time frame: Wks 12, 24 and 52

  6. Change From Baseline in Percent of Body Surface Area (BSA) Involvement

    BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).

    Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52

  7. Change From Baseline in Nail Psoriasis Severity Index (NAPSI)

    The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from range 0 to 80. Higher scores indicated more severe psoriasis.

    Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52

  8. Change From Baseline in Psoriasis Scalp Severity Index (PSSI)

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.

    Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52

  9. Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]

    QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.

    Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52

  10. Change From Baseline in Itch Numeric Rating Scale (NRS) Score

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

    Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52

  11. Change From Baseline in Dermatology Life Quality Index (DLQI) Score

    DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point increase in total score from baseline is considered clinically relevant.

    Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52

  12. Number of Participants Achieving American College of Rheumatology 20% (ACR20) Improvement [Efficacy of Ixekizumab in Participants With Psoriatic Arthritis (PsA) as Measured by ACR20]

    ACR20 response is defined as a ≥20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain visual analog scale (VAS), Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR).

    Time frame: Wks 12, 24 and 52

  13. Change From Baseline in Participants Assessment of Joint Pain Visual Analog Scale (VAS) (Efficacy of Ixekizumab in Participants With PsA Pain VAS)

    The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine).

    Time frame: Baseline, Wk 12; Baseline, Wk 52

  14. Percent of Participants Achieving PASI 75%, 90% and/or 100% Improvement

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated: 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling, with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Wk 100 and Retreatment Wk 192

  15. Percentage of Participants With sPGA (0 or 1) and sPGA (0)

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).

    Time frame: Wk 100 and Retreatment Wk 192

  16. Change From Baseline in Percent of BSA Involvement

    BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).

    Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192

  17. Change From Baseline in NAPSI

    The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all the fingernails equals the total NAPSI score with a range 0 to 80. Higher scores indicate more severe psoriasis.

    Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192

  18. Change From Baseline in PSSI

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.

    Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192

  19. Change From Baseline in QIDS-SR16 Score

    QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst) scale. The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.

    Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192

  20. Change From Baseline in Itch NRS Score

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10, (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

    Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192

  21. Change From Baseline in DLQI Score

    DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher scores indicating greater quality of life impairment. A 5-point increase in total score from baseline is considered clinically relevant.

    Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192

  22. Change From Baseline in Participants Assessment of Joint Pain VAS

    The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine).

    Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192

  23. Number of Participants Achieving ACR20

    ACR20 response is defined as ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain VAS, Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the HAQ-DI, or CRP or the ESR. Analysis population included participants with PsA who had 3 or more tender joints and 3 or more swollen joints at screening and baseline.

    Time frame: Wk 100 and Wk Retreatment Wk 192

07

Results

Posted Sep 30, 2016

Participant flow

Period 2-Induction Dosing Period (Weeks 0 up to 12), Period 3-Maintenance Dosing Period (Weeks 12 up to 52), Period 4-Drug Free Period (Weeks 52 up to 100), Period 5-Retreatment Period (up to 192 additional weeks) and Period 6-Post-Treatment Follow-Up Period up to 12 weeks after the last visit.

Period 2 - Induction
Participant flow — Period 2 - Induction
Milestone80 mg Ixekizumab (LY2439821)
Started91
Received at least 1 dose of study drug91
Erythrodermic psoriasis (ps)8
Pustular ps5
Plaque ps78
Completed90
Not completed1
Withdrew: Adverse event1
Period 3 - Maintenance
Participant flow — Period 3 - Maintenance
Milestone80 mg Ixekizumab (LY2439821)
Started90
Received at least 1 dose of study drug90
Completed83
Not completed7
Withdrew: Adverse event2
Withdrew: Lack of efficacy1
Withdrew: Physician decision2
Withdrew: Withdrawal by subject2
Period 4 - Drug Free Period
Participant flow — Period 4 - Drug Free Period
Milestone80 mg Ixekizumab (LY2439821)
Started70
Adverse event1
Physician decision1
Completed9
Not completed61
Withdrew: Relapsed61
Period 5 - Retreatment Period
Participant flow — Period 5 - Retreatment Period
Milestone80 mg Ixekizumab (LY2439821)
Started80
Completed70
Not completed10
Withdrew: Adverse event5
Withdrew: Lack of efficacy1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject3
Period 6: Follow-up
Participant flow — Period 6: Follow-up
Milestone80 mg Ixekizumab (LY2439821)
Started88
Completed79
Not completed9
Withdrew: Adverse event3
Withdrew: Lack of efficacy2
Withdrew: Physician decision1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPercentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week (Wk) 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)
percentage of participants80 mg Ixekizumab (LY2439821)
Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)98.7
SecondaryPercentage of Participants Achieving ≥75% Improvement in PASI

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region, the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Wks 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥75% Improvement in PASI
percentage of participants80 mg Ixekizumab (LY2439821)
Wk 2495.9
Wk 5292.3
SecondaryPharmacokinetics (PK): Ctrough at Steady State (Ctrough ss) of Ixekizumab

PK samples were from 1 or 2 sampling cohorts. Ctrough is the minimum observed concentration of ixekizumab at steady state. Steady-state ixekizumab trough concentrations were summarized for the induction dosing period at week 12, the time of the primary efficacy assessment. Steady-state ixekizumab trough concentrations were summarized for the maintenance dosing period at week 24.

Time frame:
Pre-dose at Wks 12 (Day 84) and Wks24 (Day 168)
Reported as:
Geometric mean · micrograms/milliliter (µg/mL)
Pharmacokinetics (PK): Ctrough at Steady State (Ctrough ss) of Ixekizumab
micrograms/milliliter (µg/mL)80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W) Cohort 29.63 ± 43.6
Wk 24 (80 mg Q4W) Cohort 13.48 ± 65.4
SecondaryNumber of Participants With Anti-Ixekizumab Antibodies

Treatment-emergent immunogenicity is defined as any occurrence of a 4-fold or 2-dilution increase in titer over the pretreatment baseline titer. In the case of a negative result at baseline, treatment-emergent immunogenicity is defined as an increase in titer to ≥1:10.

Time frame:
Baseline through Wk 52
Reported as:
Number · participants
Number of Participants With Anti-Ixekizumab Antibodies
participants80 mg Ixekizumab (LY2439821)
Plaque Ps10
Erythrodermic Ps0
Pustular Ps0
SecondaryPercent of Participants Achieving PASI 90% and 100% Improvement

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Wks 12, 24 and 52
Reported as:
Number · percentage of participants
Percent of Participants Achieving PASI 90% and 100% Improvement
percentage of participants80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W) PASI 90%83.3
Wk 12 (80 mg Q2W) PASI 100%32.1
Wk 24 (80 mg Q4W) PASI 90%90.5
Wk 24 (80 mg Q4W) PASI 100%48.6
Wk 52 (80 mg Q4W) PASI 90%80.8
Wk 52 (80 mg Q4W) PASI 100%48.7
SecondaryPercentage of Participants With Static Physician Global Assessment (sPGA) (0 or 1) or sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: sPGA)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).

Time frame:
Wks 12, 24 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Static Physician Global Assessment (sPGA) (0 or 1) or sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: sPGA)
percentage of participants80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W) sPGA (0 or 1)89.7
Wk 24 (80 mg Q4W) sPGA (0 or 1)89.2
Wk 52 (80 mg Q4W) sPGA (0 or 1)83.3
Wk 12 (80 mg Q2W) sPGA (0)35.9
Wk 24 (80 mg Q4W) sPGA (0)51.4
Wk 52 (80 mg Q4W) sPGA (0)52.6
SecondaryChange From Baseline in Percent of Body Surface Area (BSA) Involvement

BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).

Time frame:
Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Reported as:
Mean · percentage of BSA
Change From Baseline in Percent of Body Surface Area (BSA) Involvement
percentage of BSA80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)-38.3 ± 19.26
Wk 24 (80 mg Q4W)-41.2 ± 20.23
Wk 52 (80 mg Q4W)-40.8 ± 19.73
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI)

The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from range 0 to 80. Higher scores indicated more severe psoriasis.

Time frame:
Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Reported as:
Mean · units on a scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
units on a scale80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)-7.7 ± 14.65
Wk 24 (80 mg Q4W)-20.5 ± 19.42
Wk 52 (80 mg Q4W)-23.4 ± 23.67
SecondaryChange From Baseline in Psoriasis Scalp Severity Index (PSSI)

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.

Time frame:
Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Reported as:
Mean · units on a scale
Change From Baseline in Psoriasis Scalp Severity Index (PSSI)
units on a scale80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)-24.8 ± 15.12
Wk 24 (80 mg Q4W)-24.9 ± 15.11
Wk 52 (80 mg Q4W)-23.3 ± 16.48
SecondaryChange From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]

QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.

Time frame:
Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Reported as:
Mean · units on a scale
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]
units on a scale80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)-1.1 ± 3.65
Wk 24 (80 mg Q4W)-1.6 ± 3.80
Wk 52 (80 mg Q4W)-1.4 ± 3.57
SecondaryChange From Baseline in Itch Numeric Rating Scale (NRS) Score

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

Time frame:
Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Reported as:
Mean · units on a scale
Change From Baseline in Itch Numeric Rating Scale (NRS) Score
units on a scale80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)-4.7 ± 2.68
Wk 24 (80 mg Q4W)-4.8 ± 2.90
Wk 52 (80 mg Q4W)-4.8 ± 2.83
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Score

DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point increase in total score from baseline is considered clinically relevant.

Time frame:
Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Reported as:
Mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Score
units on a scale80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)-9.2 ± 5.75
Wk 24 (80 mg Q4W)-9.2 ± 6.57
Wk 52 (80 mg Q4W)-9.6 ± 6.24
SecondaryNumber of Participants Achieving American College of Rheumatology 20% (ACR20) Improvement [Efficacy of Ixekizumab in Participants With Psoriatic Arthritis (PsA) as Measured by ACR20]

ACR20 response is defined as a ≥20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain visual analog scale (VAS), Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR).

Time frame:
Wks 12, 24 and 52
Reported as:
Number · participants
Number of Participants Achieving American College of Rheumatology 20% (ACR20) Improvement [Efficacy of Ixekizumab in Participants With Psoriatic Arthritis (PsA) as Measured by ACR20]
participants80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)4
Wk 24 (80 mg Q4W)4
Wk 52 (80 mg Q4W)5
SecondaryChange From Baseline in Participants Assessment of Joint Pain Visual Analog Scale (VAS) (Efficacy of Ixekizumab in Participants With PsA Pain VAS)

The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine).

Time frame:
Baseline, Wk 12; Baseline, Wk 52
Reported as:
Mean · mm
Change From Baseline in Participants Assessment of Joint Pain Visual Analog Scale (VAS) (Efficacy of Ixekizumab in Participants With PsA Pain VAS)
mm80 mg Ixekizumab (LY2439821)
Wk 12 (80 mg Q2W)-47.3 ± 22.05
Wk 52 (80 mg Q4W)-51.0 ± 19.05
SecondaryPercent of Participants Achieving PASI 75%, 90% and/or 100% Improvement

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated: 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling, with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Wk 100 and Retreatment Wk 192
Reported as:
Number · percentage of participants
Percent of Participants Achieving PASI 75%, 90% and/or 100% Improvement
percentage of participants80 mg Ixekizumab (LY2439821)
Wk 100, PASI 757.5
Wk 100, PASI 903.0
Wk 100, PASI 1000
Wk 192, PASI 750
Wk 192, PASI 900
Wk 192, PASI 1000
SecondaryPercentage of Participants With sPGA (0 or 1) and sPGA (0)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).

Time frame:
Wk 100 and Retreatment Wk 192
Reported as:
Number · percentage of participants
Percentage of Participants With sPGA (0 or 1) and sPGA (0)
percentage of participants80 mg Ixekizumab (LY2439821)
Wk 100, sPGA(0, 1)4.5
Wk 100, sPGA(0)0
Wk 192, sPGA(0, 1)0
Wk 192, sPGA(0)0
SecondaryChange From Baseline in Percent of BSA Involvement

BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).

Time frame:
Baseline, Wk 100; Baseline, Retreatment Wk 192
Reported as:
Mean · percentage of BSA
Change From Baseline in Percent of BSA Involvement
percentage of BSA80 mg Ixekizumab (LY2439821)
Baseline, Wk 100-24.7 ± 17.32
Baseline, Wk 192-40.2 ± 21.18
SecondaryChange From Baseline in NAPSI

The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all the fingernails equals the total NAPSI score with a range 0 to 80. Higher scores indicate more severe psoriasis.

Time frame:
Baseline, Wk 100; Baseline, Retreatment Wk 192
Reported as:
Mean · units on a scale
Change From Baseline in NAPSI
units on a scale80 mg Ixekizumab (LY2439821)
Baseline, Wk 100-16.8 ± 19.87
Baseline, Wk 192-21.4 ± 26.31
SecondaryChange From Baseline in PSSI

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.

Time frame:
Baseline, Wk 100; Baseline, Retreatment Wk 192
Reported as:
Mean · units on a scale
Change From Baseline in PSSI
units on a scale80 mg Ixekizumab (LY2439821)
Baseline, Wk 100-8.5 ± 16.16
Baseline, Wk 192-23.2 ± 15.17
SecondaryChange From Baseline in QIDS-SR16 Score

QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst) scale. The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.

Time frame:
Baseline, Wk 100; Baseline, Retreatment Wk 192
Reported as:
Mean · units on a scale
Change From Baseline in QIDS-SR16 Score
units on a scale80 mg Ixekizumab (LY2439821)
Baseline, Wk 100-0.5 ± 4.02
Baseline, Wk 192-1.8 ± 3.87
SecondaryChange From Baseline in Itch NRS Score

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10, (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

Time frame:
Baseline, Wk 100; Baseline, Retreatment Wk 192
Reported as:
Mean · units on a scale
Change From Baseline in Itch NRS Score
units on a scale80 mg Ixekizumab (LY2439821)
Baseline, Wk 100-1.1 ± 2.62
Baseline, Wk 192-4.9 ± 2.59
SecondaryChange From Baseline in DLQI Score

DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher scores indicating greater quality of life impairment. A 5-point increase in total score from baseline is considered clinically relevant.

Time frame:
Baseline, Wk 100; Baseline, Retreatment Wk 192
Reported as:
Mean · units on a scale
Change From Baseline in DLQI Score
units on a scale80 mg Ixekizumab (LY2439821)
Baseline, Wk 100-2.3 ± 4.83
Baseline, Wk 192-8.9 ± 5.70
SecondaryChange From Baseline in Participants Assessment of Joint Pain VAS

The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine).

Time frame:
Baseline, Wk 100; Baseline, Retreatment Wk 192
Reported as:
Mean · mm
Change From Baseline in Participants Assessment of Joint Pain VAS
mm80 mg Ixekizumab (LY2439821)
Baseline, Wk 100-12.8 ± 39.59
Baseline, Wk 192-43.8 ± 25.66
SecondaryNumber of Participants Achieving ACR20

ACR20 response is defined as ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain VAS, Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the HAQ-DI, or CRP or the ESR. Analysis population included participants with PsA who had 3 or more tender joints and 3 or more swollen joints at screening and baseline.

Time frame:
Wk 100 and Wk Retreatment Wk 192
Reported as:
Count of participants · Participants
Number of Participants Achieving ACR20
Participants80 mg Ixekizumab (LY2439821)
Wk 1000
Wk 1920

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2439821 80mg-Combined Induction and Maintenance Periods—4/91 (4.4%)61/91 (67%)
LY2439821 80mg-Drug-Free Period—3/70 (4.3%)18/70 (25.7%)
LY2439821 80mg-Retreatment Period—9/80 (11.3%)52/80 (65%)
LY2439821 80mg-Post-Treatment Follow-Up Period—0/88 (0%)2/88 (2.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventLY2439821 80mg-Combined Induction and Maintenance PeriodsLY2439821 80mg-Drug-Free PeriodLY2439821 80mg-Retreatment PeriodLY2439821 80mg-Post-Treatment Follow-Up Period
Cytomegalovirus infectionInfections and infestations0/911/700/800/88
Hand fractureInjury, poisoning and procedural complications0/911/701/800/88
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/911/700/800/88
Diverticulum intestinal haemorrhagicGastrointestinal disorders0/910/701/800/88
Large intestine polypGastrointestinal disorders0/910/701/800/88
CholelithiasisHepatobiliary disorders1/910/701/800/88
Hyperplastic cholecystopathyHepatobiliary disorders0/910/701/800/88
PharyngotonsillitisInfections and infestations0/910/701/800/88
PneumoniaInfections and infestations0/910/701/800/88
Ankle fractureInjury, poisoning and procedural complications0/910/701/800/88
Most frequent other events
Showing 10 of 21
Most frequent other events
EventLY2439821 80mg-Combined Induction and Maintenance PeriodsLY2439821 80mg-Drug-Free PeriodLY2439821 80mg-Retreatment PeriodLY2439821 80mg-Post-Treatment Follow-Up Period
Viral upper respiratory tract infectionInfections and infestations36/916/7016/800/88
EczemaSkin and subcutaneous tissue disorders11/911/7010/800/88
InfluenzaInfections and infestations2/913/709/800/88
Eczema asteatoticSkin and subcutaneous tissue disorders3/910/709/800/88
Injection site reactionGeneral disorders8/910/702/800/88
Seborrhoeic dermatitisSkin and subcutaneous tissue disorders8/910/701/800/88
UrticariaSkin and subcutaneous tissue disorders8/913/703/800/88
Hepatic function abnormalHepatobiliary disorders0/911/707/800/88
FolliculitisInfections and infestations3/912/707/800/88
HypertensionVascular disorders1/910/707/800/88

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)80 mg Ixekizumab (LY2439821)
Mean46.2 ± 11.89
Sex: Female, Male
Sex: Female, Male(Participants)80 mg Ixekizumab (LY2439821)
Female21
Male70
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)80 mg Ixekizumab (LY2439821)
Hispanic or Latino0
Not Hispanic or Latino91
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)80 mg Ixekizumab (LY2439821)
American Indian or Alaska Native0
Asian91
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)80 mg Ixekizumab (LY2439821)
Japan91
Psoriasis Area and Severity Index (PASI) Total Score
Psoriasis Area and Severity Index (PASI) Total Score(units on a scale)80 mg Ixekizumab (LY2439821)
Mean27.24 ± 10.545
Static Physician Global Assessment (sPGA) Score
Static Physician Global Assessment (sPGA) Score(participants)80 mg Ixekizumab (LY2439821)
0: Clear0
1: Minimal0
2: Mild1
3: Moderate26
4: Severe53
5: Very Severe11
Percentage (%) of Body Surface Area (BSA)
Percentage (%) of Body Surface Area (BSA)(units on a scale)80 mg Ixekizumab (LY2439821)
Mean45.5 ± 23.22

6 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ehime, 791-0295, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 830-0011, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gifu, 501-1194, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 060-0814, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 514-8507, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ishikawa, 920-8641, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iwate, 020-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 259-1193, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 860-0811, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 606-8397, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miyazaki, 889-1692, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagano, 390-8621, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 700-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka-Pref, 589, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 565-0871, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 350-0495, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 162-8666, Japan
09

References and documents

Publications

  • Honma M, Cai Z, Burge R, Zhu B, Yotsukura S, Torisu-Itakura H. Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J). Dermatol Ther (Heidelb). 2020 Dec;10(6):1397-1404. doi: 10.1007/s13555-020-00441-4. Epub 2020 Sep 10. PubMed 32910360 ↗
  • Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, Heffernan M. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1148-55. doi: 10.1111/jdv.12773. Epub 2014 Oct 30. PubMed 25355284 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Sep 2013 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 3 years after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2012
First posted
Jun 20, 2012
Start
Jun 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2017
Results delay requested
Apr 25, 2014
Results first posted
Sep 30, 2016
Last update
Sep 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01624233
Responsible party
Sponsor
First posted
Jun 20, 2012
Start date
Jun 2012
Primary completion
Sep 2013
Completion
Sep 2017
Results posted
Sep 30, 2016
Last update
Sep 10, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion